Levofloxacin

Brand names: Levaquin · Active ingredient: Levofloxacin

In short: Levofloxacin tablets are indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae,or Streptococcus pneumoniae. Adjunctive th

Forms & strengthsLevofloxacin tablets USP, 250 mg are terra pink colored capsule shaped, biconvex film-coated tablets, debossed with ‘13’ on one side and ‘T’ on the other side. …
LabelPD-Rx Pharmaceuticals, Inc.
Label updatedNov 09, 2026

What is Levofloxacin used for?

Levofloxacin tablets are indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible

Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae,or

Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where

Pseudomonas aeruginosais a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended

.

Levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible

Staphylococcus aureus, Streptococcus pneumoniae(including multi-drug-resistant

Streptococcus pneumoniae[MDRSP]),

Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila,or

Mycoplasma pneumoniae .

MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2

ndgeneration cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.

Levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to

Streptococcus pneumoniae(excluding multi-drug-resistant isolates [MDRSP]),

Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae,or

Chlamydophila pneumoniae

. …

âš  Boxed warning (FDA's strongest warning)

Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together

,

including:

Tendinitis and tendon rupture

Peripheral neuropathy

Central nervous system effects

Discontinue levofloxacin immediately and avoid the use of fluoroquinolones, including levofloxacin, in patients who experience any of these serious adverse reactions

Fluoroquinolones, including levofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid levofloxacin in patients with a known history of myasthenia gravis

.

Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions

,

reserve levofloxacin for use in patients who have no alternative treatment options for the following indications:

Uncomplicated urinary tract infection

Acute bacterial exacerbation of chronic bronchitis

Acute bacterial sinusitis

.

Levofloxacin dosage

The usual dose of levofloxacin tablets is 250 mg, 500 mg, or 750 mg administered orally every 24 hours, as indicated by infection and described in Table 1.

These recommendations apply to patients with creatinine clearance ≥ 50 mL/minute. For patients with creatinine clearance less than 50 mL/min, adjustments to the dosing regimen are required

.

Type of Infection

* | Dosed Every 24 hours | Duration (days)

†

Nosocomial Pneumonia | 750 mg | 7 to 14

Community Acquired Pneumonia

‡ | 500 mg

‡ | 7 to 14

‡

Community Acquired Pneumonia

§ | 750 mg

§ | 5

§

Complicated Skin and Skin Structure Infections (SSSI) | 750 mg | 7 to 14

Uncomplicated SSSI | 500 mg | 7 to 10

Chronic Bacterial Prostatitis | 500 mg | 28

Inhalational Anthrax (Post-Exposure), adult and pediatric patients weighing 50 kg

Þ,ßor greater

Pediatric patients weighing 30 kg to less than 50 kg

Þ,ß | 500 mg

see Table 2 below (2.2) | 60

ß

60

ß

Plague, adult and pediatric patients weighing 50 kg

àor greater Pediatric patients weighing 30 kg to less than 50 kg | 500 mg

see Table 2 below (2.2) | 10 to 14

10 to 14

Complicated Urinary Tract Infection (cUTI) or

Acute Pyelonephritis (AP)

¶ | 750 mg | 5

Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

# | 250 mg

# | 10

#

Uncomplicated Urinary Tract Infection | 250 mg | 3

Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) | 500 mg | 7

Acute Bacterial Sinusitis (ABS) | 750 mg | 5

500 mg | 10 to 14

*

Due to the designated pathogens

.

†

Sequential therapy (intravenous levofloxacin to oral levofloxacin tablets) may be instituted at the discretion of the healthcare provider.

‡ Due to methicillin-susceptible

Staphylococcus aureus, Streptococcus pneumoniae(including multi-drug-resistant isolates [MDRSP]),

Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila,or

Mycoplasma pneumoniae .

§ Due to

Streptococcus pneumoniae(excluding multi-drug-resistant isolates [MDRSP]),

Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae .

¶ This regimen is indicated for cUTI due to

Escherichia coli, Klebsiella pneumoniae, Proteus mirabilisand AP due to

E. coli,including cases with concurrent bacteremia.

# This regimen is indicated for cUTI due to

Enterococcus faecalis, Enterococcus cloacae, Escherichia coli,

Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa; and for AP due to

E. coli.

Þ Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized

B. anthracis. This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit

. …

How to take Levofloxacin — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (

Medication Guide).

Serious Adverse Reactions

Advise patients to stop taking levofloxacin if they experience an adverse reaction and to call their healthcare provider for advice on completing the full course of treatment with another antibacterial drug.

Inform patients of the following serious adverse reactions that have been associated with levofloxacin or other fluoroquinolone use:

Disabling and Potentially Irreversible Serious Adverse Reactions That May Occur Together: Inform patients that disabling and potentially irreversible serious adverse reactions, including tendinitis and tendon rupture, peripheral neuropathies, and central nervous system effects, have been associated with use of levofloxacin and may occur together in the same patient. Inform patients to stop taking levofloxacin immediately if they experience an adverse reaction and to call their healthcare provider. …

Warnings & precautions

Do not take this medicine if: Levofloxacin tablets are contraindicated in persons with known hypersensitivity to levofloxacin, or other quinolone antibacterials

.

Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion). These reactions can occur within hours to weeks after starting levofloxacin. Patients of any age or without pre-existing risk factors have experienced these adverse reactions

.

Discontinue levofloxacin immediately at the first signs or symptoms of any serious adverse reaction. In addition, avoid the use of fluoroquinolones, including levofloxacin, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones.

Fluoroquinolones, including levofloxacin, have been associated with an increased risk of tendinitis and tendon rupture in all ages

.

This adverse reaction most frequently involves the Achilles tendon and has also been reported with the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendon sites. Tendinitis or tendon rupture can occur within hours or days of starting levofloxacin or as long as several months after completion of fluoroquinolone therapy. Tendinitis and tendon rupture can occur bilaterally.

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. …

Levofloxacin side effects

The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:

Disabling and Potentially Irreversible Serious Adverse Reactions

Tendinitis and Tendon Rupture

Peripheral Neuropathy

Central Nervous System Effects

Exacerbation of Myasthenia Gravis

Other Serious and Sometimes Fatal Reactions

Hypersensitivity Reactions

Hepatotoxicity

Risk of Aortic Aneurysm and Dissection

Clostridium difficile-Associated Diarrhea

Prolongation of the QT Interval

Musculoskeletal Disorders in Pediatric Patients

Blood Glucose Disturbances

Photosensitivity/Phototoxicity

Development of Drug Resistant Bacteria

Crystalluria and cylindruria have been reported with quinolones, including levofloxacin. Therefore, adequate hydration of patients receiving levofloxacin should be maintained to prevent the formation of a highly concentrated urine

.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to levofloxacin in 7537 patients in 29 pooled Phase 3 clinical trials. The population studied had a mean age of 50 years (approximately 74% of the population was < 65 years of age), 50% were male, 71% were Caucasian, 19% were Black. …

Drug interactions

While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine may substantially interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. These agents should be taken at least two hours before or two hours after oral levofloxacin administration.

No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for R- and S- warfarin was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of warfarin on levofloxacin absorption and disposition was observed. However, there have been reports during the postmarketing experience in patients that levofloxacin enhances the effects of warfarin. …

About this medicine

Levofloxacin tablets are synthetic antibacterial agents for oral administration. Chemically, levofloxacin, a chiral fluorinated carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug substance ofloxacin. The chemical name is (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate.

Figure 1: The Chemical Structure of Levofloxacin

The molecular formula is C

18H

20FN

3O

4• ½ H

2O and the molecular weight is 370.38. Levofloxacin USP is a pale or bright yellow, crystalline powder. The molecule exists as a zwitterion at the pH conditions in the small intestine.

The data demonstrate that from pH 0.6 to 5.8, the solubility of levofloxacin USP is essentially constant (approximately 100 mg/mL). Levofloxacin USP is considered

soluble to freely solublein this pH range, as defined by USP nomenclature. Above pH 5.8, the solubility increases rapidly to its maximum at pH 6.7 (272 mg/mL) and is considered

freely solublein this range. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 814450ae-439e-4a5d-8c60-9b21b6f14be5. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin